Evommune, Inc. (NYSE: EVMN) announced that its Phase 2b clinical trial of EVO756 in adults with moderate-to-severe chronic spontaneous urticaria ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE